Steve King: Just to expand on that a little bit, our stated goal has been ex-U.S. partnering, to primarily keep as much of the U.S. rights as we can, and that remains intact. The reason obviously at this point of partnering is to allow us to expand what we are doing with bavituximab program. We’ve obviously got a number of new clinical studies we’ve identified as being important to start over the coming months, in order so that we can have the data from those studies by the time we unblind the SUNRISE study, but also to be able to run addl. studies in other combinations and other indications, because clearly that’s where the value of the program can be driven upward is through addl. indications and utilization of bavituximab across many different treatment paradigms.
News 
Market Data 
Discover 
AI
